ClinicalTrials.gg
CompletedNCT05086107Updated Jan 18, 2023

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

A Phase 1 interventional study of BV100 in Renal Impairment, sponsored by BioVersys AG. Completed at 1 site in Hungary. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by BioVersys AG · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Renal Insufficiency with a site in Hungary — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Hungary.

Enrollment
9th of 20
48 · median 42
Started
2021
with 1 other
Phase 1
9 of 23
none open now
Registered
21st of 23
by date
Lead sponsor
1 of 23
BioVersys AG

Among the 23 studies in Renal Insufficiency with a site in Hungary, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2021, is one of 9 in phase 1, and was the 21st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 23 studies in Renal Insufficiency with a site in Hungary are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Renal Insufficiency with a site in Hungary, or all of them as a file.
02

Study summary

To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100

Read the detailed description

To investigate the pharmacokinetics (PK) of rifabutin and excipient in subjects with renal impairment after single intravenous (IV) infusion of BV10=. In addition to investigate the safety and tolerability of BV100 in subjects with renal impairment and to investigate the PK of 25-acyl-rifabutin metabolite in subjects with renal impairment after single intravenous (IV) infusion of BV100

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are able to understand and follow instructions during the study.
  2. Subjects who signed .
  3. Male subjects ≥18 and ≤75 years of age; female subjects ≥18 and ≤75 years of age of non-, defined as follows:

    • female subjects 50 years of age or older, in menopause for 24 consecutive months, and not receiving any hormone replacement therapy within 24 months prior to inclusion into the study
    • female subjects who underwent surgical sterilization
    • female subjects who underwent hysterectomy
    • female subjects with documented premature ovarian failure
  4. Weight within a range of 19.0-35.0 kg/m2, range limits inclusive.
  5. Having had no febrile or infectious illness for at least 7 days prior to dosing.
  6. The subject will be available to complete the study.
  7. The subject commits to comply with the restrictions and requirements of the protocol and, in the opinion of the study physician, will be able to complete the study.

    Control volunteers with normal renal function, in addition to criteria of "All subjects":

  8. Estimated (eGFR) according to MDRD:

    • ≥90 mL/min (normal renal function)
  9. Control subjects have to be in good health or in stable condition, in the opin-ion of the study physician, as determined by medical history, , vital signs, physical examination, and clinical laboratory tests. Subjects having chronic conditions should have an onset of at least 3 months prior to Screening, clini-cally stable, and well-controlled.

    Renally impaired patient volunteers, in addition to criteria of "All subjects":

  10. Estimated glomerular filtration rate (eGFR) according to MDRD:

    • 60-89 mL/min (mild renal impairment)
    • 30-59 mL/min (moderate renal impairment)
    • 15-29 mL/min (severe renal impairment)
    • \<15 mL/min (requiring dialysis)
  11. Stable renal impairment, defined as no change in dis-ease status within 2 weeks from Screening, as judged by the Investigator.
  12. Subjects with systolic blood pressure ≥ 90 mmHg and diastolic blood pressure ≥ 50 mmHg.
  13. Patients with chronic diseases / conditions other than renal impairment can be included, provided that these diseases / conditions are stable, well-controlled, and do not interfere with the study objectives or the subject's over-all safety, as judged by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to give .
  2. As a result of the medical screening process, the study physician considered the subject unfit for the study.
  3. Pregnant or lactating women or men with female partners who are lactating or are pregnant.
  4. Known or suspected history of to rifabutin or or to drugs of a similar chemical class including rifampicin, rifapentine, rifaximin; history of allergic reactions leading to hospitalisation or any other allergic con-ditions (including drug allergies, asthma, eczema, anaphylactic reactions but excluding untreated, asymptomatic, seasonal allergies) which the Investigator considers may affect the safety of the subject and / or the outcome of the study.
  5. History of antibiotic-associated diarrhoea within one year.
  6. Subjects with significant abnormalities (history, or evidence of sec-ond-degree heart block of Mobitz type II, third degree heart block, or any ab-normality considered relevant by the Investigator), > 460 ms, PR > 200 ms, or QRS duration > 120 ms.
  7. History of symptomatic, chronic or recurrent infection (e.g. nausea, vomit-ing, diarrhoea, infection with fever) or any viral, bacterial, fungal or parasitic infection within 30 days prior to admission to the clinical unit.
  8. A positive screening serology test for surface antigen (HBsAg), virus (HCV), or (HIV)-1 and / or 2.
  9. Positive drugs-of-abuse or alcohol screen.
  10. History of epilepsy, other neurological disorders, or neuropsychiatric con-ditions.
  11. History of seizures.
  12. Subjects having used megadose vitamins (i.e. 20 to 600 times the recom-mended daily supplement dose) within 7 days prior to dosing, unless in the opinion of the study physician the medication does not interfere with the study procedures or compromise safety
  13. Volunteers who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes, utilized within 30 days of IMP administration.
  14. Regular use within 3 months of IMP administration of a enzyme modifier - any inhibitor, moderate or strong inducer, and sensitive or moder-ately sensitive substrate, as listed in Section 11.3 'Prohibited concomitant med-ications'.
  15. Volunteers who have participated in a clinical study involving administra-tion of an drug within the following time period prior to the dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  16. Volunteers who consume more than 21 units of alcohol per week, or who have a significant history of alcohol abuse (one unit of alcohol equals ½ pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 30 mL of 40% of alcohol by volume distilled spirits).
  17. Excessive consumption of caffeine- or xanthine-containing food or bever-ages (> 5 cups of coffee a day or equivalent), or inability to stop consuming from 48 hours prior to study treatment administration.
  18. Subjects who smoke more than 10 cigarettes a day.
  19. Any use of drugs-of-abuse or alcohol abuse within 2 years prior to the first admission to the clinical unit.
  20. Inability to understand or communicate reliably with the Investigator or considered by the Investigator to be unable to or unlikely to co-operate with the requirements of the study.
  21. Any other conditions or factors which in the opinion of the Investigator may interfere with study conduct. Failure to satisfy the Investigator of fitness to participate for any other reason.
  22. Any significant blood loss, donation of one unit (450 mL) of blood or more, or receipt of transfusion of any blood or blood products within 60 days, or plasma donation within 7 days prior to the first admission to the clinical study site.
  23. Volunteers who are employees or immediate family members of the study site or Sponsor.

    Control volunteers with normal renal function, in addition to criteria of "All subjects":

  24. Supine systolic blood pressure > 150 mmHg or \< 90 mmHg, or diastolic blood pressure > 100 mmHg or \< 50 mmHg at Screening or on Day 1, prior to dosing (any abnormal blood pressure results may be repeated arbitrarily, and if the repeat result is within the normal range, it is not considered to have met the exclusion criterion). Pulse rate > 100 or \< 50 beats per minute at Screening or on Day 1, prior to dosing.
  25. Screening laboratory values should not exceed 1.5 x , and the eventu-al deviation should be deemed as being clinically non-significant. Any abnor-mal value of these parameters may be repeated arbitrarily, and if the repeated result is within the allowed range, it is not considered to have met the exclusion criterion.
  26. Volunteers who have received any new prescribed systemic or topical medication within 4 weeks of the first dose administration.

    Renally impaired patient volunteers, in addition to criteria of "All subjects":

  27. Acute renal failure (as judged by the Investigator).
  28. History of kidney transplant regardless of functionality.
  29. History of nephrectomy.
  30. Start of any new medication or any changes to current dosages within 14 days prior to study drug administration.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Group 1

    subjects with mild renal impairment (eGFR: 60 to 89 mL/min)

    Drug: BV100

  • Experimental
    Group 2

    subjects with moderate renal impairment (eGFRr: 30 to 59 mL/min)

    Drug: BV100

  • Experimental
    Group 3

    subjects with severe renal impairment (eGFR: 15-29 mL/min)

    Drug: BV100

  • Experimental
    Group 4

    subjects with normal renal function (eGFR: ≥ 90 mL/min)

    Drug: BV100

  • Experimental
    Group 5

    subjects with end stage renal disease (ESRD) eGFR: \<15 mL/min requiring dialysis (with BV100 dosing and PK during the dialysis-free interval)

    Drug: BV100

  • Experimental
    Group 6

    subjects with ESRD (eGFRr: \<15 mL/min) requiring dialysis (with BV100 dosing and PK on the day of dialysis)

    Drug: BV100

Interventions

  • DrugBV100

    Rifabutin for infusion

    Also known as: Rifabutin for Infusion

06

What researchers measure

Primary outcomes

  1. To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 96 hours

  2. To characterize the single dose pharmacokinetic profile of rifabutin

    Peak Plasma Concentration (Cmax)

    Time frame: 96 hours

Secondary outcomes

  1. To investigate the safety and tolerability of single intravenous ascending doses of BV100 assessed by the nature, occurrence, and severity of treatment-emergent adverse events

    Safety and Tolerability

    Time frame: 7 days

  2. To determine the plasma concentration of the main metabolite 25-O-Desacetyl-Rifabutin in plasma in subjects with renal impairment

    Pharmacokinetics

    Time frame: 96 hours

07

Study locations

1 site
  • CRU Hungary Kft., Early Phase Unit
    Miskolc, H-3529, Hungary
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in May 2022, 7 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 20, 2021
StartActual
Oct 8, 2021
Primary completionActual
May 30, 2022
CompletionActual
Jan 16, 2023
Last update
Jan 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05086107
Lead sponsor
BioVersys AG
Collaborators
CRU Hungary Kft, CRU Hungary Early Phase Unit
Responsible party
Sponsor
First posted
Oct 20, 2021
Start date
Oct 8, 2021
Primary completion
May 30, 2022
Completion
Jan 16, 2023
Last update
Jan 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BV100

Start the discussion